While alterations in SWI/SNF composition have wide-spread roles in tumor biology, these findings describe a very confined and specific vulnerability of the residual SWI/SNF complex in cancers containing inactivating ARID1A mutations. The gene discussed is SMARCA1; the disease is neoplasm.